Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer (THREAD)
Summary
The purpose of this phase I trial is to study the side effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery.
General Information
NCT#: NCT03825289
Study ID: HCI116898
Trial Phase: Phase I
Trial Sponsor: Novartis Pharmaceuticals, University of Utah
Therapies Used in This Trial: Hydroxychloroquine, Trametinib